Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Secures $1.2 Million in SBIR Grants

NEW YORK, Nov. 10 (GenomeWeb News) - Detroit R&D said today that it has received $1.2 million in new phase I and phase II SBIR grants, which will support the company's continued genomic and proteomic research into xenobiotic and toxic substances metabolism.


The first phase I grant will provide $100,000 to support of the development of antibody chips to screen drug-metabolizing enzymes, said Detroit R&D. The second phase I grant is for $400,000, and will be used to find markers for fetal alcohol syndrome.


Detroit R&D said that the phase II grant, worth $750,000, was awarded to help in the development of frog embryo DNA microarrays as a tool for toxicogenomic studies.



The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.